Figure 4. IPI-926 is an effective maintenance therapy.

Mice bearing tumors derived from patients diagnosed with serous ovarian cancer were randomized into 4 cohorts (n = 4–6 animals per treatment cohort) with matched tumor volumes and subjected to the indicated treatment regimens. Three independent papillary serous ovarian cancer samples, SOC12 (A), SOC13 (B) and SOC14 (C) were used as biological replicates. Cohorts were initially treated with vehicle alone (Control), paclitaxel and carboplatinum (T/C) alone, IPI-926 alone or T/C+IPI-926 as indicated. The last T/C dose was delivered on day 14 (indicated by the dotted line). Percent change in tumor volume represents the change in tumor volume relative to the tumor volume at the beginning of the experiment. Error bars represent the standard error of the mean (S.E.M). Significance was determined using a Wilcoxon rank sum test.